Omnicell (OMCL)
(Delayed Data from NSDQ)
$26.57 USD
-0.19 (-0.71%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $26.59 +0.02 (0.08%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
OMCL 26.57 -0.19(-0.71%)
Will OMCL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OMCL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OMCL
Omnicell (OMCL) Banks on Product Launches, Global Growth
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
OMCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
Other News for OMCL
Analysts Conflicted on These Healthcare Names: Repare Therapeutics (RPTX), Omnicell (OMCL) and Oscar Health (OSCR)
OMCL Crosses Above Average Analyst Target
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Omnicell (OMCL), Tandem Diabetes Care (TNDM) and Amgen (AMGN)
OMCL July 19th Options Begin Trading
Buy Rating on Omnicell Affirmed: Innovation and Growth Outlook Fuel Optimism for FY24 and Beyond